Trajectory Next has received $125,000 in funding from Tedco to drive technologies including an ankle robot and voice-controlled heart disease management software.

Taikang Life and Lilly Asia Ventures, which backed the initial $59.7m series B round last year, have also contributed to a $35m series B+ round of Hangzhou Just Biotherapeutics.

Lilly Asia Ventures and existing investor Alexandria Venture Investments have taken part in a $65m series C round for metabolic disease treatment developer Metacrine.

Uniseed and MRCF have become founding investors in University of Melbourne's precision medicine spinout Certa Therapeutics.

The prescription monitoring device developer and Purdue affiliate previously disclosed approximately $1.8m in funding through securities filings.

Pfizer Ventures is set to invest $600m in biotechnology, with neuroscience a key focus, bringing the size of its corporate venturing activities to more than $1bn.

The $31m series A round will help set up an oncology franchise across four to five cities throughout India.

Camp4 has attracted capital from investors such as Kraft Group to continue development of its drug discovery platform based on work at MIT and Harvard Medical School.

Pfizer and Takeda, which previously backed a $15m series A, have returned to back a $76m series B round for Cortexyme.

Cytrellis has raised $28.5m from investors including pharmaceutical developer Merz as it continues clinical trials on its handheld dermatological device for aging skin.